Insider Trading › WCRX › Insiders
WCRX
WCRX·Insider activity
—
No end-of-day price on record
WCRX
Insider purchases and sales on the price
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
WCRXS&P 500 (rebased)
Insider BuyInsider SellForm 144 · planned sale
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
No open-market insider purchases or sales of WCRX were filed in the last 180 days. Newest filing Jul 2, 2013 (13 years ago).
Net Insider Buying by Quarter
Shares bought (+) or sold (−) on the open market by WCRX insiders · Form 4 · last two years
No open-market insider buys or sells in the last two years.
On Record
$0Purchases · 180 days
$0Sales · 180 days
318Open-market transactions on record
0Insiders filing · 180 days
Purchases (code P) and sales (code S) of WCRX common stock reported on Form 4, with Form 5 annual catch-ups. Grants, option exercises, gifts and tax withholding are not shown. Dollars are shares × the stated price; a price outside anything the stock traded at that day is withheld (n/c).
Insider Transactions
318 on record · newest trade first · the newest 300 shown
AllPurchasesSalesOfficers & directors
| Insider | Type | Shares | Price | Value | Held after | Traded | Filed | |
|---|---|---|---|---|---|---|---|---|
| Halstead MichaelSenior V.P., Corp. Development | Sale | −366 | $19.88 | $7K | 51.8Kdirect | Jul 1, 2013 | Jul 2, 2013 | Form 4 ↗ |
| Sullivan Ryan TVP, General Counsel & Secr. | Sale | −169 | $19.88 | $3K | 26.5Kdirect | Jul 1, 2013 | Jul 2, 2013 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −703 | $13.41 | $9K | 144.8Kdirect | Apr 1, 2013 | Apr 1, 2013 | Form 4 ↗ |
| CONNAUGHTON JOHNDirector | Sale | −10.6M | $13.47 | $142.7M | 0indirect | Mar 4, 2013 | Mar 6, 2013 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,666 | $13.38 | $22K | 181.2Kdirect | Mar 1, 2013 | Mar 4, 2013 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −15.9K | $13.46 | $214K | 145.5Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Rodriguez Rama FranciscoSenior V.P., Tech. Operations | Sale | −820 | $13.46 | $11K | 30.5Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −2,354 | $13.46 | $32K | 77.6Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −1,324 | $13.46 | $18K | 204.8Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −1,390 | $13.46 | $19K | 108.3Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,728 | $13.46 | $23K | 99.7Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −1,747 | $13.46 | $24K | 52.2Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −1,728 | $13.46 | $23K | 56.5Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −4,674 | $13.46 | $63K | 132.6Kdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −18.7K | $13.46 | $252K | 2.3Mdirect | Feb 28, 2013 | Mar 1, 2013 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −419 | $14.53 | $6K | 109.7Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −691 | $14.53 | $10K | 182.9Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −1,045 | $14.53 | $15K | 80.0Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −553 | $14.53 | $8K | 206.2Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −767 | $14.53 | $11K | 101.4Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −2,562 | $14.53 | $37K | 129.7Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −767 | $14.53 | $11K | 58.3Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −419 | $14.53 | $6K | 54.0Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −1,969 | $14.53 | $29K | 137.3Kdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −7,928 | $14.53 | $115K | 2.3Mdirect | Feb 19, 2013 | Feb 21, 2013 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −996 | $14.18 | $14K | 94.6Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −808 | $14.18 | $11K | 191.2Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,010 | $14.18 | $14K | 168.1Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −998 | $14.18 | $14K | 38.9Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,010 | $14.18 | $14K | 86.7Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −1,377 | $14.18 | $20K | 65.6Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −998 | $14.18 | $14K | 43.6Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −13.8K | $14.18 | $196K | 132.2Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −2,840 | $14.18 | $40K | 101.5Kdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −9,125 | $14.18 | $129K | 2.2Mdirect | Feb 1, 2013 | Feb 4, 2013 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −465 | $13.38 | $6K | 192.0Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −489 | $13.38 | $7K | 66.9Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −351 | $13.38 | $5K | 95.6Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −586 | $13.38 | $8K | 169.1Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −591 | $13.38 | $8K | 87.7Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −282 | $13.38 | $4K | 44.6Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −320 | $13.38 | $4K | 39.9Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −308 | $13.38 | $4K | 146.0Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −1,907 | $14.42 | $27K | 146.3Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −2,208 | $13.38 | $30K | 104.4Kdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −8,470 | $13.38 | $113K | 2.2Mdirect | Jan 30, 2013 | Jan 31, 2013 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −621 | $13.50 | $8K | 96.0Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,166 | $13.50 | $16K | 169.7Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −949 | $13.50 | $13K | 67.4Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,222 | $13.50 | $16K | 88.3Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −839 | $13.50 | $11K | 192.5Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −488 | $13.50 | $7K | 44.9Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −488 | $13.50 | $7K | 40.2Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −4,305 | $13.50 | $58K | 106.6Kdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −13.9K | $13.50 | $188K | 2.2Mdirect | Jan 22, 2013 | Jan 23, 2013 | Form 4 ↗ |
| Murray Stephen PDirector | Sale | −6.5M | $11.41 | $74.1M | 0indirect | Nov 28, 2012 | Nov 30, 2012 | Form 4 ↗ |
| Murray Stephen PDirector | Sale | −5.0M | $11.66 | $58.3M | 6.5Mindirect | Nov 20, 2012 | Nov 20, 2012 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −264 | $13.55 | $4K | 68.4Kdirect | Oct 1, 2012 | Oct 1, 2012 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −77 | $13.55 | $1K | 40.7Kdirect | Oct 1, 2012 | Oct 1, 2012 | Form 4 ↗ |
| Bain Capital Integral Investors II, L.P.10% owner | Sale | −12.9M | $13.10 | $168.9M | 11.5Mindirect | Sep 11, 2012 | Sep 13, 2012 | Form 4 ↗ |
| CONNAUGHTON JOHNDirector · 10% owner | Sale | −12.9M | $13.10 | $168.9M | 11.5Mindirect | Sep 11, 2012 | Sep 13, 2012 | Form 4 ↗ |
| THL WC (Cayman), L.P.10% owner | Sale | −14.0M | $13.10 | $183.4M | 11.5Mindirect | Sep 11, 2012 | Sep 13, 2012 | Form 4 ↗ |
| ABBRECHT TODD MDirector | Sale | −14.0M | $13.10 | $183.4M | 11.5Mindirect | Sep 11, 2012 | Sep 13, 2012 | Form 4 ↗ |
| Hara IzumiSenior V.P. | Sale | −127.0K | $13.10 | $1.7M | 73.9Kdirect | Sep 11, 2012 | Sep 12, 2012 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −309.2K | $13.10 | $4.1M | 110.9Kdirect | Sep 11, 2012 | Sep 12, 2012 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −147.6K | $13.10 | $1.9M | 89.5Kdirect | Sep 11, 2012 | Sep 12, 2012 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −23.5K | $13.10 | $308K | 170.9Kdirect | Sep 11, 2012 | Sep 12, 2012 | Form 4 ↗ |
| Murray Stephen PDirector | Sale | −14.0M | $13.10 | $183.4M | 11.5Mindirect | Sep 11, 2012 | Sep 12, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −1.5M | $13.10 | $19.6M | 675.2Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −215.4K | $13.10 | $2.8M | 176.8Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −950.1K | $13.10 | $12.4M | 779.9Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −193.5K | $13.10 | $2.5M | 87.2Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −1.1M | $13.10 | $15.0M | 940.1Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −267.0K | $13.10 | $3.5M | 219.1Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −373.8K | $13.10 | $4.9M | 306.8Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −2.2M | $13.10 | $29.1M | 1.8Mdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −7.9M | $13.10 | $103.4M | 6.5Mdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −14.0M | $13.10 | $183.4M | 11.5Mdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −1.5M | $13.10 | $19.6M | 675.2Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −215.4K | $13.10 | $2.8M | 176.8Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −950.1K | $13.10 | $12.4M | 779.9Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −193.5K | $13.10 | $2.5M | 87.2Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −1.1M | $13.10 | $15.0M | 940.1Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −267.0K | $13.10 | $3.5M | 219.1Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −373.8K | $13.10 | $4.9M | 306.8Kdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −2.2M | $13.10 | $29.1M | 1.8Mdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −7.9M | $13.10 | $103.4M | 6.5Mdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −14.0M | $13.10 | $183.4M | 11.5Mdirect | Sep 11, 2012 | Sep 11, 2012 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −355 | $17.96 | $6K | 40.8Kdirect | Jul 2, 2012 | Jul 2, 2012 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −703 | $16.95 | $12K | 148.2Kdirect | Apr 2, 2012 | Apr 3, 2012 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −558 | $17.00 | $9K | 193.3Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −386 | $17.00 | $7K | 96.6Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −973 | $17.00 | $17K | 68.6Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −710 | $17.00 | $12K | 200.9Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −710 | $17.00 | $12K | 237.2Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −710 | $17.00 | $12K | 45.3Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −725 | $17.00 | $12K | 41.1Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −2,485 | $17.00 | $42K | 148.9Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −1,827 | $17.00 | $31K | 420.1Kdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −5,320 | $17.00 | $90K | 2.3Mdirect | Mar 1, 2012 | Mar 2, 2012 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −409 | $16.82 | $7K | 97.0Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −1,030 | $16.82 | $17K | 69.6Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −752 | $16.82 | $13K | 201.6Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −752 | $16.82 | $13K | 237.9Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −590 | $16.82 | $10K | 193.9Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −752 | $16.82 | $13K | 46.0Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −677 | $16.82 | $11K | 194.4Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −409 | $16.82 | $7K | 41.9Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −2,561 | $16.82 | $43K | 146.5Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −1,933 | $16.82 | $33K | 422.0Kdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −5,628 | $16.82 | $95K | 2.3Mdirect | Feb 21, 2012 | Feb 23, 2012 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −351 | $16.45 | $6K | 76.6Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −480 | $16.45 | $8K | 49.9Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −635 | $16.45 | $10K | 181.6Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −579 | $16.45 | $10K | 217.8Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −504 | $16.45 | $8K | 173.7Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −281 | $16.45 | $5K | 26.0Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −579 | $16.45 | $10K | 174.3Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −320 | $16.45 | $5K | 21.5Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| van Zoonen Marinus JohannesPresident, Europe/Int'l & Mkt. | Sale | −2,215 | $16.45 | $36K | 38.7Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −2,187 | $16.45 | $36K | 365.4Kdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −8,317 | $16.45 | $137K | 2.1Mdirect | Jan 30, 2012 | Jan 31, 2012 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −621 | $17.32 | $11K | 77.0Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −1,169 | $17.32 | $20K | 182.2Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,225 | $17.32 | $21K | 218.4Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −933 | $17.32 | $16K | 50.3Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −487 | $17.32 | $8K | 26.3Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,169 | $17.32 | $20K | 174.8Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −487 | $17.32 | $8K | 21.8Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −921 | $17.32 | $16K | 174.2Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −4,149 | $17.32 | $72K | 367.6Kdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −13.7K | $17.32 | $236K | 2.1Mdirect | Jan 23, 2012 | Jan 24, 2012 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,146 | $16.66 | $19K | 219.7Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Finance | Sale | −411 | $16.66 | $7K | 26.8Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,042 | $16.66 | $17K | 176.0Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −452 | $16.66 | $8K | 22.3Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Fenton AndrewSenior V.P., CIO | Sale | −558 | $16.66 | $9K | 77.6Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −839 | $16.66 | $14K | 51.3Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −908 | $16.66 | $15K | 175.1Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −1,095 | $16.66 | $18K | 183.4Kdirect | Jan 11, 2012 | Jan 12, 2012 | Form 4 ↗ |
| Fawzi Mahdi BPresident, Research & Develop. | Sale | −2,418 | $16.80 | $41K | 57.8Kdirect | Oct 21, 2011 | Oct 24, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P., Quality | Sale | −270 | $14.03 | $4K | 52.1Kdirect | Oct 3, 2011 | Oct 3, 2011 | Form 4 ↗ |
| Halstead MichaelSenior V.P., Corp. Development | Sale | −78 | $14.03 | $1K | 22.7Kdirect | Oct 3, 2011 | Oct 3, 2011 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −79.6K | $22.29 | $1.8M | 176.0Kdirect | Jun 10, 2011 | Jun 13, 2011 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −100.0K | $22.41 | $2.2M | 255.6Kdirect | Jun 9, 2011 | Jun 13, 2011 | Form 4 ↗ |
| van Zoonen Marinus JohannesPres., Europe/Int'l&Glob. Mkt. | Sale | −703 | $23.30 | $16K | 40.9Kdirect | Apr 1, 2011 | Apr 4, 2011 | Form 4 ↗ |
| CONNAUGHTON JOHNDirector · 10% owner | Sale Amended | −466.2K | n/c | — | 25.5Mindirect | Mar 30, 2011 | Apr 1, 2011 | Form 4 ↗ |
| Bain Capital (WC) Netherlands B.V10% owner | Sale Amended | −466.2K | n/c | — | 25.5Mindirect | Mar 30, 2011 | Apr 1, 2011 | Form 4 ↗ |
| Bain Capital (WC) Netherlands B.V10% owner | Sale | −446.2K | n/c | — | 25.5Mindirect | Mar 30, 2011 | Apr 1, 2011 | Form 4 ↗ |
| CONNAUGHTON JOHNDirector · 10% owner | Sale | −446.2K | n/c | — | 25.5Mindirect | Mar 30, 2011 | Apr 1, 2011 | Form 4 ↗ |
| THOMAS H LEE ADVISORS ALTERNATIVE V LTD LDC10% owner | Sale | −466.2K | n/c | — | 25.5Mindirect | Mar 30, 2011 | Apr 1, 2011 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −3,713 | $23.25 | $86K | 184.4Kdirect | Mar 30, 2011 | Mar 31, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −512 | $23.25 | $12K | 28.0Kindirect | Mar 30, 2011 | Mar 31, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −1,031 | $23.25 | $24K | 52.4Kdirect | Mar 30, 2011 | Mar 31, 2011 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −3,546 | $23.25 | $82K | 177.0Kdirect | Mar 30, 2011 | Mar 31, 2011 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −15.4K | $23.25 | $358K | 371.7Kdirect | Mar 30, 2011 | Mar 31, 2011 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −18.0K | $23.25 | $419K | 371.6Kdirect | Mar 30, 2011 | Mar 31, 2011 | Form 4 ↗ |
| Bruno Anthony DExec. V.P., Corp. Development | Sale | −16.8K | $23.25 | $392K | 308.1Kdirect | Mar 30, 2011 | Mar 31, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −27.4K | n/c | — | 1.5Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −7,173 | n/c | — | 399.4Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −31.6K | n/c | — | 1.8Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −3,538 | n/c | — | 197.0Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −38.1K | n/c | — | 2.1Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −8,891 | n/c | — | 495.0Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −12.4K | n/c | — | 693.0Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −74.1K | n/c | — | 4.1Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −262.9K | n/c | — | 14.6Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| JPMP MASTER FUND MANAGER L P10% owner | Sale | −466.2K | n/c | — | 25.5Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −27.4K | n/c | — | 1.5Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −7,173 | n/c | — | 399.4Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −31.6K | n/c | — | 1.8Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −3,538 | n/c | — | 197.0Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −38.1K | n/c | — | 2.1Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −8,891 | n/c | — | 495.0Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −12.4K | n/c | — | 693.0Kdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −74.1K | n/c | — | 4.1Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −262.9K | n/c | — | 14.6Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP10% owner | Sale | −466.2K | n/c | — | 25.5Mdirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| Murray Stephen PDirector | Sale | −466.2K | n/c | — | 25.5Mindirect | Mar 30, 2011 | Mar 30, 2011 | Form 4 ↗ |
| CONNAUGHTON JOHNDirector · 10% owner | Sale | −6.9M | $22.44 | $155.3M | 26.0Mindirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| Bain Capital (WC) Luxembourg Sarl10% owner | Sale | −6.9M | $22.44 | $155.3M | 26.0Mindirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −461.9K | $22.44 | $10.4M | 1.5Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −121.0K | $22.44 | $2.7M | 399.4Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −533.5K | $22.44 | $12.0M | 1.8Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −59.7K | $22.44 | $1.3M | 197.0Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −643.1K | $22.44 | $14.4M | 2.1Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −149.2K | $22.44 | $3.3M | 495.0Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −209.9K | $22.44 | $4.7M | 693.0Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −1.2M | $22.44 | $28.0M | 4.1Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −4.4M | $22.44 | $99.5M | 14.6Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| JPMP CAPITAL CORP10% owner | Sale | −7.9M | $22.44 | $176.4M | 26.0Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −461.9K | $22.44 | $10.4M | 1.5Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −121.0K | $22.44 | $2.7M | 399.4Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −533.5K | $22.44 | $12.0M | 1.8Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −59.7K | $22.44 | $1.3M | 197.0Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −643.1K | $22.44 | $14.4M | 2.1Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −149.2K | $22.44 | $3.3M | 495.0Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −209.9K | $22.44 | $4.7M | 693.0Kdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −1.2M | $22.44 | $28.0M | 4.1Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −4.4M | $22.44 | $99.5M | 14.6Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN LP10% owner | Sale | −7.9M | $22.44 | $176.4M | 26.0Mdirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| MURRAY STEPHENDirector | Sale | −7.9M | $22.44 | $176.4M | 26.0Mindirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| THL WC (Dutch) B.V.10% owner | Sale | −7.9M | n/c | — | 26.0Mindirect | Mar 16, 2011 | Mar 18, 2011 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −63.5K | n/c | — | 188.2Kdirect | Mar 16, 2011 | Mar 17, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −8,774 | n/c | — | 28.6Kindirect | Mar 16, 2011 | Mar 17, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −17.6K | n/c | — | 53.4Kdirect | Mar 16, 2011 | Mar 17, 2011 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −60.7K | n/c | — | 180.6Kdirect | Mar 16, 2011 | Mar 17, 2011 | Form 4 ↗ |
| Bruno Anthony DExec. V.P., Corp. Development | Sale | −400.0K | n/c | — | 325.0Kdirect | Mar 16, 2011 | Mar 17, 2011 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −400.0K | n/c | — | 387.1Kdirect | Mar 16, 2011 | Mar 17, 2011 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −400.0K | n/c | — | 389.6Kdirect | Mar 16, 2011 | Mar 17, 2011 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Global Finance | Sale | −278 | $23.35 | $6K | 11.5Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −474 | $23.35 | $11K | 55.4Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| van Zoonen Marinus JohannesPres., Europe/Int'l&Glob. Mkt. | Sale | −2,215 | $23.35 | $52K | 21.1Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −572 | $23.35 | $13K | 227.2Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −572 | $23.35 | $13K | 341.5Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −572 | $23.35 | $13K | 205.1Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −2,152 | $23.35 | $50K | 746.7Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Bruno Anthony DExec. V.P., Corp. Development | Sale | −2,152 | $23.35 | $50K | 684.6Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −2,152 | $23.35 | $50K | 749.2Kdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −8,228 | $23.35 | $192K | 2.0Mdirect | Jan 31, 2011 | Feb 1, 2011 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −1,054 | $23.62 | $25K | 342.1Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Fuhrmann RochelleSenior V.P., Global Finance | Sale | −485 | $23.62 | $11K | 11.8Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,164 | $23.62 | $27K | 227.7Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −929 | $23.62 | $22K | 55.8Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,219 | $23.62 | $29K | 205.7Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −4,096 | $23.62 | $97K | 751.4Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −4,096 | $23.62 | $97K | 748.9Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Bruno Anthony DExec. V.P., Corp. Development | Sale | −4,097 | $23.62 | $97K | 686.8Kdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −13.6K | $23.62 | $321K | 2.0Mdirect | Jan 21, 2011 | Jan 24, 2011 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −1,030 | $23.85 | $25K | 343.1Kdirect | Jan 11, 2011 | Jan 11, 2011 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,133 | $23.85 | $27K | 206.9Kdirect | Jan 11, 2011 | Jan 11, 2011 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,030 | $23.85 | $25K | 228.9Kdirect | Jan 11, 2011 | Jan 11, 2011 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −829 | $23.85 | $20K | 56.8Kdirect | Jan 11, 2011 | Jan 11, 2011 | Form 4 ↗ |
| Fawzi Mahdi BPresident, Research & Develop. | Sale | −2,467 | $24.20 | $60K | 23.8Kdirect | Oct 21, 2010 | Oct 21, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −15.0M | $21.48 | $322.2M | 10.2Mindirect | Sep 30, 2010 | Oct 4, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −322.8K | $22.50 | $7.3M | 25.2Mindirect | Sep 29, 2010 | Oct 1, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −575.0K | $22.53 | $13.0M | 25.5Mindirect | Sep 28, 2010 | Sep 30, 2010 | Form 4 ↗ |
| AlpInvest Partners CS Investments 2003 C.V.10% owner | Sale | −651.0K | $22.68 | $14.8M | 0direct | Sep 27, 2010 | Nov 1, 2010 | Form 4 ↗ |
| AlpInvest Partners CS Investments 2003 C.V.10% owner | Sale | −1.6M | $22.78 | $37.6M | 651.0Kdirect | Sep 24, 2010 | Nov 1, 2010 | Form 4 ↗ |
| AlpInvest Partners CS Investments 2003 C.V.10% owner | Sale | −393.2K | $22.85 | $9.0M | 2.3Mdirect | Sep 23, 2010 | Nov 1, 2010 | Form 4 ↗ |
| AlpInvest Partners CS Investments 2003 C.V.10% owner | Sale | −481.2K | $22.92 | $11.0M | 2.7Mdirect | Sep 22, 2010 | Nov 1, 2010 | Form 4 ↗ |
| Gilligan Claire ASenior V.P. Global Quality | Sale | −956 | $23.05 | $22K | 55.6Kdirect | Sep 22, 2010 | Sep 22, 2010 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −1,171 | $23.05 | $27K | 344.1Kdirect | Sep 22, 2010 | Sep 22, 2010 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,422 | $23.05 | $33K | 208.0Kdirect | Sep 22, 2010 | Sep 22, 2010 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,171 | $23.05 | $27K | 229.9Kdirect | Sep 22, 2010 | Sep 22, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −124.7K | $22.01 | $2.7M | 26.1Mindirect | Sep 14, 2010 | Sep 16, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −38.7K | $22.05 | $854K | 26.2Mindirect | Sep 13, 2010 | Sep 14, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −109.8K | $22.03 | $2.4M | 26.3Mindirect | Sep 10, 2010 | Sep 14, 2010 | Form 4 ↗ |
| AlpInvest Partners CS Investments 2003 C.V.10% owner | Sale | −229.9K | $26.73 | $6.1M | 3.2Mdirect | Mar 25, 2010 | Apr 6, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −8.6M | $25.19 | $217.3M | 26.4Mindirect | Mar 25, 2010 | Mar 25, 2010 | Form 4 ↗ |
| Bruno Anthony DExec. V.P., Corp. Development | Sale | −4,120 | $28.17 | $116K | 667.9Kdirect | Jan 21, 2010 | Jan 22, 2010 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −13.7K | $28.17 | $385K | 1.9Mdirect | Jan 21, 2010 | Jan 22, 2010 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −4,120 | $28.17 | $116K | 732.5Kdirect | Jan 21, 2010 | Jan 22, 2010 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −4,120 | $28.17 | $116K | 742.0Kdirect | Jan 21, 2010 | Jan 22, 2010 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −1,052 | $28.17 | $30K | 339.2Kdirect | Jan 21, 2010 | Jan 22, 2010 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,217 | $28.17 | $34K | 203.4Kdirect | Jan 21, 2010 | Jan 22, 2010 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,162 | $28.17 | $33K | 225.0Kdirect | Jan 21, 2010 | Jan 22, 2010 | Form 4 ↗ |
| Cross Leland HSenior V.P., Tech. Operations | Sale | −1,039 | $28.32 | $29K | 340.3Kdirect | Jan 11, 2010 | Jan 12, 2010 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −1,143 | $28.32 | $32K | 204.6Kdirect | Jan 11, 2010 | Jan 12, 2010 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel. | Sale | −1,039 | $28.32 | $29K | 226.2Kdirect | Jan 11, 2010 | Jan 12, 2010 | Form 4 ↗ |
| CREDIT SUISSE AG/10% owner | Sale | −4.4M | n/c | — | 35.1Mindirect | Nov 25, 2009 | Dec 1, 2009 | Form 4 ↗ |
| CONNAUGHTON JOHNDirector · 10% owner | Sale | −3.9M | n/c | — | 33.8Mindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| BCIP Trust Associates III10% owner | Sale | −3.9M | n/c | — | 33.8Mindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| THOMAS H LEE ADVISORS ALTERNATIVE V LTD LDC10% owner | Sale | −4.1M | n/c | — | 33.2Mindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| ABBRECHT TODD MDirector | Sale | −4.2M | n/c | — | 33.3Mindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| THL ADVISORS ALTERNATIVE V LP10% owner | Sale | −4.1M | n/c | — | 33.2Mindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| THOMAS H LEE ALTERNATIVE FUND V LP10% owner | Sale | −3.3M | n/c | — | 26.0Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −248.3K | n/c | — | 2.0Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −65.0K | n/c | — | 520.3Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −286.8K | n/c | — | 2.3Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −32.1K | n/c | — | 256.7Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −345.7K | n/c | — | 2.8Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −80.6K | n/c | — | 644.9Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −112.8K | n/c | — | 902.9Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −671.6K | n/c | — | 5.4Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −2.4M | n/c | — | 19.1Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JPMP GLOBAL INVESTORS L P10% owner | Sale | −4.2M | n/c | — | 33.8Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| MURRAY STEPHENDirector | Sale | −4.2M | n/c | — | 33.8Mindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| MURRAY STEPHENDirector | Sale | −4.2M | n/c | — | 33.8Mindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −248.3K | n/c | — | 2.0Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −65.0K | n/c | — | 520.3Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −286.8K | n/c | — | 2.3Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −32.1K | n/c | — | 256.7Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −345.7K | n/c | — | 2.8Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −80.6K | n/c | — | 644.9Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −112.8K | n/c | — | 902.9Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −671.6K | n/c | — | 5.4Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −2.4M | n/c | — | 19.1Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| JP MORGAN PARTNERS GLOBAL INVESTORS LP10% owner | Sale | −4.2M | n/c | — | 33.8Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −8,935 | n/c | — | 71.5Kindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −8,935 | n/c | — | 71.5Kindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Reichel Carl WPresident, Pharmaceuticals | Sale | −146.7K | n/c | — | 736.6Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Howard Alvin DSr. V.P., Regulatory Affairs | Sale | −24.5K | n/c | — | 205.7Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Herendeen PaulExec. V.P. and CFO | Sale | −147.8K | n/c | — | 746.1Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Hara IzumiSr. VP, Gen. Counsel & Sec. | Sale | −27.6K | n/c | — | 229.3Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Ellman HermanSenior V.P., Clinical Devel | Sale | −27.1K | n/c | — | 227.2Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Bruno Anthony DExec. V.P., Corp. Development | Sale | −18.3K | n/c | — | 142.4Kindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Bruno Anthony DExec. V.P., Corp. Development | Sale | −138.1K | n/c | — | 672.0Kdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −231.0K | n/c | — | 300.0Kindirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
| Boissonneault Roger MCEO & President · Director | Sale | −91.7K | n/c | — | 1.9Mdirect | Nov 25, 2009 | Nov 30, 2009 | Form 4 ↗ |
Source: SEC EDGAR Form 4 and Form 5 filings, SEC's quarterly bulk dataset through Jun 30, 2026, and KeyVex's half-hourly read of new filings since. Every row links its filing. Amendments are marked. Nothing here is a recommendation. All insider activity, market-wide →